Data Driven Utilization Management, Purpose Built for Oncology
Oncology Analytics® provides health plans, providers, and patients with a data-driven, utilization management solution that delivers real-world, evidence-based analytics focused exclusively for oncology
FDA Oncology Drug Approvals
Bringing together science, technology and analytics to support evidence-based decision-making in oncology utilization management addresses the two biggest challenges associated with making informed and timely patient treatment decisions: speed and evidence. This type of approach requires deep analytics and insights into a health plan’s cancer drug spend to ensure that anti-cancer therapies are based on science and evidence-based protocols specific to the patient’s unique circumstances and needs.
Oncology Analytics offers critical technology and services that address the primary challenges and gaps health plans face in advancing a data-driven strategy for oncology utilization management:
Report shows 75% increase in new drug approvals compared to Q4 2020; Over 35% granted accelerated approval by the FDA
Company increased revenue YOY by 40%, delivered over $100 million of financial impact to clients, and added 1.1 million incremental new members on prior auth platform ATLANTA, March 2, 2021 — Oncology Analytics, a leading data analytics and technology-enabled services...
Articles & Press
As coronavirus disease 2019 (COVID-19) has transformed the world we live in, so too has it changed the paradigms of treatment for many cancers.
The following article is the fifth in a five-part series on The Top Five Ways for Health Plans to Manage Oncology Drug Costs While Improving Member Treatment Options.
Date: Wednesday, June 30, 2021
Time: 1:00 PM EST
Date: Thursday, June 3, 2021
Time: 2:00 PM EST